No Data
Google predicts that quantum computing will reshape the future within five years, and the Industry is expected to迎来 a period of Gold development.
① Julian Kelly, head of Google's Quantum AI Hardware department, recently stated that in about five years, quantum computers will experience a real breakthrough, including conducting cutting-edge physics research and generating new types of data. ② Huaan analysis pointed out that quantum information technology is expected to become an important core technology for China to "overtake on a bend" and gain discourse power in the Industry Chain within the Global technology industry.
Shanghai Fudan Forward S&T (600624.SH): Termination of acquisition of 51% equity in Beautiful Life.
On March 6, Gelonghui reported that Shanghai Fudan Forward S&T (600624.SH) announced that in order to enhance the company's profitability, comprehensive competitiveness, and sustainable development capabilities, and to expand the CSI SWS Health Care index, forming Business synergy, the company held the 12th meeting of the 10th Board of Directors and the 6th meeting of the 10th Supervisory Board on April 28, 2022, and approved the proposal on acquiring 51% equity of Ningbo Beautiful Life Medical Biotechnology Development Co., Ltd. The Board of Directors and the Supervisory Board agreed for the company to invest 114,192,102.03 yuan from self-raised funds to acquire Ningbo Beautiful Life Medical Biotechnology Development Co., Ltd.
Revenues Not Telling The Story For Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) After Shares Rise 26%
Shanghai Fudan Forward S&T (600624.SH): The holding subsidiary's Pharmaceutical has passed the consistency evaluation for generic drugs.
On February 5th, GELON Group announced that its subsidiary Shanghai Fudan Forward S&T Pharmaceutical Co., Ltd. (referred to as "the Pharmaceutical Company") received the approval notice from the National Medical Products Administration regarding the supplementary application for Tamoxifen Citrate Tablets (referred to as "the Pharmaceutical"). This Pharmaceutical has passed the consistency evaluation of the quality and efficacy of generic drugs. Tamoxifen Citrate Tablets are listed in the National Medical Insurance Catalogue (2024 Edition) as a Class A Pharmaceutical and belong to the class of non-steroidal anti-estrogen drugs, used for the treatment of recurrent or metastatic breast cancer and as adjuvant therapy after surgery for early breast cancer.
Fudan Fuhua: Shanghai Fudan Fuhua Technology Co., Ltd. 2024 Annual Results Forecast
Shanghai Fudan Fuhua Technology Co., Ltd. 2024 Annual Results Forecast
Is Shanghai Fudan Forward S&T (SHSE:600624) Using Too Much Debt?